Eliem Therapeutics, Inc. () Stock Analysis | Price, Returns, Financials & Key Metrics

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

257.56 k

Shareholding (Mar 2025)

FII

2.62%

Held by 29 FIIs

DII

85.54%

Held by 13 DIIs

Promoter

5.70%

How big is Eliem Therapeutics, Inc.?

22-Jun-2025

As of Jun 18, Eliem Therapeutics, Inc. has a market capitalization of 81.09 million, with net sales of 0.00 million and a net profit of -92.98 million over the last four quarters. The company reported shareholder's funds of 211.88 million and total assets of 217.19 million as of Dec 24.

What does Eliem Therapeutics, Inc. do?

22-Jun-2025

Eliem Therapeutics, Inc. is a micro-cap company in the Pharmaceuticals & Biotechnology industry, currently reporting a net profit loss of $21 million and a market cap of $81.09 million. Key financial metrics include a negative P/E ratio, a 0.00% dividend yield, and a debt-to-equity ratio of -0.51.

Is Eliem Therapeutics, Inc. technically bullish or bearish?

20-Sep-2025

As of September 8, 2025, Eliem Therapeutics, Inc. shows a mildly bullish trend with mixed signals from various indicators, having a year-to-date return of 24.44% compared to the S&P 500's 12.22%, but underperforming over the past year with a return of -71.93%.

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.Unlock 29 Markets

Dashboard

Unrated Stock - No Analysis Available

Mojo Parameters

Stock DNA

Industry

Pharmaceuticals & Biotechnology

Market cap

USD 167 Million ()

P/E

NA (Loss Making)

Industry P/E

Dividend Yield

0.00%

Debt Equity

-0.45

Return on Equity

-23.37%

Price to Book

0.90

Revenue and Profits:

Net Sales:

(Quarterly Results - Jun 2025)

Net Profit:

-9 Million

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

-29.1%

6 Months

34.11%

1 Year

-45.08%

2 Years

-33.72%

3 Years

-34.01%

4 Years

-83.74%

5 Years

0.0%

Eliem Therapeutics, Inc. for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

Is Eliem Therapeutics, Inc. technically bullish or bearish?

As of 8 September 2025, the technical trend for Eliem Therapeutics, Inc. has changed from sideways to mildly bullish. The current stance is mildly bullish, driven by a bullish MACD on the weekly timeframe and a bullish daily moving average. However, the weekly RSI is bearish, indicating some short-term weakness. The Bollinger Bands show a mildly bullish signal on the weekly but are mildly bearish on the monthly, suggesting mixed signals. The KST is bullish weekly but bearish monthly, and Dow Theory indicates a mildly bearish stance on the weekly while being mildly bullish on the monthly. In terms of performance, Eliem Therapeutics has a year-to-date return of 24.44%, significantly outperforming the S&P 500's 12.22% during the same period, although it has underperformed over the past year with a return of -71.93% compared to the S&P 500's 17.14%....

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

-100.00%

EBIT Growth (5y)

-151.11%

EBIT to Interest (avg)

100.00

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

-0.51

Sales to Capital Employed (avg)

Tax Ratio

Dividend Payout Ratio

Pledged Shares

Institutional Holding

99.42%

ROCE (avg)

ROE (avg)

Valuation key factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

0.49

EV to EBIT

0.08

EV to EBITDA

0.08

EV to Capital Employed

-0.04

EV to Sales

PEG Ratio

Dividend Yield

ROCE (Latest)

Negative Capital Employed

ROE (Latest)

-19.64%

Technicals key factors

Indicator

Weekly

Monthly

MACD

Mildly Bearish

Mildly Bullish

RSI

No Signal

Bullish

Bollinger Bands

Mildly Bearish

Bearish

Moving Averages

Mildly Bullish (Daily)

KST

Mildly Bearish

Bearish

Dow Theory

No Trend

OBV

No Trend

Mildly Bearish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot : Mar 2025

Shareholding Compare (%holding)

Majority shareholders

Domestic Funds

Held in 20 Schemes (6.14%)

Foreign Institutions

Held by 29 Foreign Institutions (2.62%)

Strategic Entities with highest holding

Highest Public shareholder

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is 0.00% vs 0.00% in Jun 2024",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is 84.15% vs -955.77% in Jun 2024",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Jun'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-10.60",
          "val2": "-4.70",
          "chgp": "-125.53%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "-51.70",
          "chgp": "100.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-8.70",
          "val2": "-54.90",
          "chgp": "84.15%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is 0.00% vs 0.00% in Dec 2023",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is -110.54% vs 22.35% in Dec 2023",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-27.00",
          "val2": "-40.30",
          "chgp": "33.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "-55.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-73.90",
          "val2": "-35.10",
          "chgp": "-110.54%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY

Jun'25

Jun'24

Change(%)

Net Sales

0.00

Operating Profit (PBDIT) excl Other Income

-10.60

-4.70

-125.53%

Interest

0.00

Exceptional Items

0.00

-51.70

100.00%

Consolidate Net Profit

-8.70

-54.90

84.15%

Operating Profit Margin (Excl OI)

0.00%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in quarter ended Jun 2025 is 0.00% vs 0.00% in Jun 2024

Consolidated Net Profit

YoY Growth in quarter ended Jun 2025 is 84.15% vs -955.77% in Jun 2024

All Quarterly Results

Annual Results Snapshot (Consolidated) - Dec'24

Dec'24

Dec'23

Change(%)

Net Sales

0.00

Operating Profit (PBDIT) excl Other Income

-27.00

-40.30

33.00%

Interest

0.00

Exceptional Items

-55.00

0.00

Consolidate Net Profit

-73.90

-35.10

-110.54%

Operating Profit Margin (Excl OI)

0.00%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Dec 2024 is 0.00% vs 0.00% in Dec 2023

Consolidated Net Profit

YoY Growth in year ended Dec 2024 is -110.54% vs 22.35% in Dec 2023

All Annual Results

Company CV

About Eliem Therapeutics, Inc.

Eliem Therapeutics, Inc.

Pharmaceuticals & Biotechnology

No Details Available.

Company Coordinates

No Company Details Available

Eliem Therapeutics, Inc.

1Day

52 Week

CASH

FII

DII

Promoter

How big is Eliem Therapeutics, Inc.?

Watch in Real-Time

What does Eliem Therapeutics, Inc. do?

Is Eliem Therapeutics, Inc. technically bullish or bearish?

MarketsMojo — Loved in India, Now Global

Dashboard

Mojo Parameters

Stock DNA

Total Returns (Price + Dividend)

Risk Adjusted Returns v/s

News

Is Eliem Therapeutics, Inc. technically bullish or bearish?

Announcements

Corporate Actions

Quality key factors

Valuation key factors

Technicals key factors

Shareholding Snapshot : Mar 2025

Shareholding Compare (%holding)

Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY

Annual Results Snapshot (Consolidated) - Dec'24

About Eliem Therapeutics, Inc.

Company Coordinates